Simple and Practical Mental Health

The BEST resource for mental health clinicians

  • REVIEWS
  • MENUS
  • RESOURCES
    • Side effect handouts
    • Patient handouts: Main page
    • How to find treatment resources
    • Rating scales and questionnaires for mental health clinicians
    • BEST books
    • BEST apps/ websites
  • NEWS
  • QUESTIONS?
  • DAILY EMAILS
  • FAQ
  • LOG IN
  • JOIN

Levomilnacipran (Fetzima®): An organized list of references

  1. Prescribing Information: http://www.allergan.com/assets/pdf/fetzima_pi#page=1
  2. Review article: Mago R, Mahajan R, Thase M. Levomilnacipran for the treatment of major depressive disorder. Expert Rev Clin Pharmacol. 2014;7(2):137-45.
  3. Review article: Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2013;67(11):1089–1104.
  4. Randomized controlled trial: Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013;74(3):242-248.
  5. Randomized controlled trial: Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci 2014;39(1):40–49.
  6. Randomized controlled trial: Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2013;74(4):363-369.
  7. Randomized controlled trial: Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder. J Clin Psychopharmacol. 2014;34(1):1-10.
  8. Randomized controlled trial: Gommoll C, Bose A, Li H, Edwards J. A randomized double-blind, placebo-controlled, flexible-dose study of levomilnacipran in patients with major depressive disorder. Poster presented at; 24th Annual US Psychiatric and Mental Health Congress; 7 – 10 November 2011; Las Vegas, NV, USA.
  9. Randomized controlled trial: Fava M, Freeman M, Gommoll C, et al. Levomilnacipran ER for fatigue associated with major depressive disorder: a double-blind, randomized, placebo- and active-controlled study. Poster presented at: 26th Annual US Psychiatric and Mental Health Congress; 30 September – 3 October 2013; Las Vegas, NV, USA.
  10. Relapse prevention ­– randomized controlled trial: Shiovitz T, Greenberg WM, Chen C, Forero G, Gommoll CP. A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder. Innov Clin Neurosci. 2014;11(1-2):10-22.
  11. One year open-label extension study: Mago R, Forero G, Greenberg WM, Gommoll C, Chen C. Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study. Clin Drug Investig. 2013;33(10):761-771.

Related Pages

Levomilnacipran (Fetzima®): Basic Information

Levomilnacipran (Fetzima®): Efficacy

Levomilnacipran (Fetzima®): Pharmacological Effects

Levomilnacipran (Fetzima®): Pharmacokinetics

Levomilnacipran (Fetzima®): Drug Interactions

Levomilnacipran (Fetzima®): Adverse Effects

Antidepressants: Index and Links

Psychopharmacology: Index and Links


Share this:

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email

Follow us on social media

  • Facebook
  • LinkedIn
  • Twitter

Copyright 2016 to 2025: Simple and Practical Medical Education, LLC. All rights reserved.